MediciNova Inc (MNOV)
1.83
0.00 (0.00%)
USD |
NASDAQ |
Nov 15, 16:00
1.86
+0.03
(+1.64%)
After-Hours: 20:00
MediciNova Research and Development Expense (TTM): 5.873M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 5.873M |
| March 31, 2024 | 5.963M |
| December 31, 2023 | 5.658M |
| September 30, 2023 | 6.020M |
| June 30, 2023 | 7.679M |
| March 31, 2023 | 8.508M |
| December 31, 2022 | 9.144M |
| September 30, 2022 | 8.908M |
| June 30, 2022 | 8.543M |
| March 31, 2022 | 8.505M |
| December 31, 2021 | 8.538M |
| September 30, 2021 | 8.558M |
| June 30, 2021 | 8.708M |
| March 31, 2021 | 8.379M |
| December 31, 2020 | 7.485M |
| September 30, 2020 | 7.516M |
| June 30, 2020 | 6.429M |
| March 31, 2020 | 5.696M |
| December 31, 2019 | 6.079M |
| September 30, 2019 | 4.465M |
| June 30, 2019 | 5.684M |
| March 31, 2019 | 5.598M |
| December 31, 2018 | 5.626M |
| September 30, 2018 | 6.569M |
| June 30, 2018 | 5.467M |
| Date | Value |
|---|---|
| March 31, 2018 | 4.985M |
| December 31, 2017 | 4.224M |
| September 30, 2017 | 3.658M |
| June 30, 2017 | 3.279M |
| March 31, 2017 | 3.344M |
| December 31, 2016 | 3.519M |
| September 30, 2016 | 3.841M |
| June 30, 2016 | 3.538M |
| March 31, 2016 | 3.373M |
| December 31, 2015 | 3.017M |
| September 30, 2015 | 2.886M |
| June 30, 2015 | 3.193M |
| March 31, 2015 | 3.232M |
| December 31, 2014 | 3.260M |
| September 30, 2014 | 3.415M |
| June 30, 2014 | 3.307M |
| March 31, 2014 | 3.418M |
| December 31, 2013 | 3.366M |
| September 30, 2013 | 3.206M |
| June 30, 2013 | 3.293M |
| March 31, 2013 | 3.831M |
| December 31, 2012 | 5.013M |
| September 30, 2012 | 5.676M |
| June 30, 2012 | 6.483M |
| March 31, 2012 | 7.039M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
5.658M
Minimum
Dec 2023
9.144M
Maximum
Dec 2022
7.484M
Average
7.679M
Median
Jun 2023
Research and Development Expense (TTM) Benchmarks
| BioVie Inc | 23.10M |
| BridgeBio Pharma Inc | 506.34M |
| Ikena Oncology Inc | 40.57M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |